Blood and blood treatments

Fuchs, 2021, Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: The BMT CTN 1101 trial, Blood, 137, 420, 10.1182/blood.2020007535 Klamroth, 2021, Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: Results from the phase 3 PROPEL study, Blood, 137, 1818, 10.1182/blood.2020005673 Li, 2021, Intra-articular injections of platelet-rich plasma vs. hyaluronic acid in patients with knee osteoarthritis: Preliminary follow-up results at 6-months, Experimental and Therapeutic Medicine, 21, 598, 10.3892/etm.2021.10030 Liu, 2021, CD19-specific CAR T cells that express a PD-1/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 27, 473, 10.1158/1078-0432.CCR-20-1457 Lopes, 2021, Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial, The Lancet, 397, 2253, 10.1016/S0140-6736(21)01203-4 Malvehy, 2021, Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: Findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma, Journal for Immunotherapy of Cancer, 9, 10.1136/jitc-2020-001621 Mei, 2021, A multicenter, randomized phase iii trial of Hetrombopag: A novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia, Journal of Hematology & Oncology, 14, 37, 10.1186/s13045-021-01047-9 Peng, 2021, Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: A single-arm phase II study, Cancer Communications, 41, 1173, 10.1002/cac2.12214 Sun, 2021, Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: A multicentre, randomised, open-label, phase 2 trial, The Lancet Haematology, 8, e289, 10.1016/S2352-3026(21)00030-2 The American Red Cross